Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.  
Advertisement

Related Content

Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J
Teva To Launch First Generic EpiPen In 'Coming Months'; FDA Heralds Approval Of Complex Product
Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted
Insmed’s Amikacin Gains US FDA Panel Nod For Refractory Lung Disease
Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out
Other ASCO 2018 Highlights – It’s Not All IO
Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales
Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion
Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel